Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ljupco Veskovski"'
Autor:
Ljupco Veskovski, Ingvar Jakobsson, Per‐Ola Andersson, Therese Gustafsson, Annelie Sedigh, Dorota Knut‐Bojanowska, Markus Hansson, Cecilie Hveding Blimark, Ulf‐Henrik Mellqvist
Publikováno v:
eJHaem, Vol 5, Iss 3, Pp 455-461 (2024)
Abstract Multiple myeloma (MM) is a disease, that at times poses diagnostic and monitoring challenges. Over the last decades laboratory methods have been expanded with serum free light chain (FLC) analysis. Alerted by two index cases with clinical im
Externí odkaz:
https://doaj.org/article/387a9bc3496b46fbb69cbe3bad7c7c13
Autor:
Göran Wålinder, Anna Genell, Gunnar Juliusson, Ronald Svensson, Antonio Izarra Santamaria, Jacob Crafoord, Kristina Carlson, Dorota Knut‐Bojanowska, Ljupco Veskovski, Birgitta Lauri, Johan Lund, Ingemar Turesson, Markus Hansson, Cecilie Hveding Blimark, Hareth Nahi
Publikováno v:
Cancer Reports, Vol 5, Iss 11, Pp n/a-n/a (2022)
Abstract Background We wanted to evaluate if health care for multiple myeloma (MM) patients is equal in different regions of Sweden. Aim To study differences in survival for MM depending on health care region and early use of modern treatment. Method
Externí odkaz:
https://doaj.org/article/ffd053207c734b989745cde79bf3b206
Autor:
Daniel Malmodin, Ulf-Henrik Mellqvist, Per-Ola Andersson, Anders Pedersen, Ljupco Veskovski, Ingemar Turesson
Publikováno v:
Experimental Hematology. 97:79-88.e8
The metabolome, which is the final down-stream global product of metabolic processes in organisms, is not sufficiently described in multiple myeloma (MM) patients. The aim of this study was, therefore, to study the serum metabolomic profile using pro
Autor:
Mina Ali, Konstantinos Lemonakis, Markus Hansson, Anna-Karin Wihlborg, Urban Gullberg, Ulf-Henrik Mellqvist, Ingemar Turesson, Björn Nilsson, Ljupco Veskovski
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 9, Iss 8, Pp 1-3 (2019)
Blood Cancer Journal, Vol 9, Iss 8, Pp 1-3 (2019)
Autor:
Daniel Malmodin, Ulf-Henrik Mellqvist, Per-Ola Andersson, Anders Pedersen, Ingemar Turesson, Ljupco Veskovski
Publikováno v:
Blood. 134:1771-1771
Background. The prognosis in multiple myeloma (MM) has improved significantly in the last two decades. However, the outcome after initial high dose melphalan followed by autologous stem cell infusion (ASCT) is very diverse and prognostic markers, bas
Autor:
Paolo Corradini, Enrique M. Ocio, Krzysztof Warzocha, Tontanai Numbenjapon, Suporn Chuncharunee, Hans Salwender, Jonathan L. Kaufman, Tatiana Shelekhova, Monika Sopala, Ming Chung Wang, Darrell White, Robert L. Schlossman, Meral Beksac, Thanyaphong Na Nakorn, Jian Hou, Hermann Einsele, Bourras Rezki Bengoudifa, V. Hungria, Kwee Yong, Daryl Tan, Jesús F. San-Miguel, Meletios A. Dimopoulos, Sung-Soo Yoon, Joan Bladé, Florence Binlich, Peter Gimsing, Wiesław Wiktor Jędrzejczak, Stefano Pulini, Richard Leblanc, Andreas Günther, Wenming Chen, Je-Jung Lee, Hareth Nahi, Jamie Cavenagh, Ashraf Elghandour, Ljupco Veskovski, Lugui Qiu, Sagar Lonial, Paul G. Richardson, Javier de la Rubia, Jae Hoon Lee, Claudia Corrado, Noppadol Siritanaratkul, Philippe Moreau, Sang Kyun Sohn
Publikováno v:
LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Background Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic antimyeloma activity when combined with bortezomib and dexamethasone. We aimed to compare panobinostat, bortezomib, and dexamethasone with
Autor:
Cecilie Blimark, Martin Hjorth, Ulf-Henrik Mellqvist, Ljupco Veskovski, Per-Ola Andersson, Mats Brune, Jan Westin, Erik Holmberg, Stig Rödjer
Publikováno v:
European Journal of Haematology. 87:117-122
Introduction: Today, a number of therapeutic options are available as the patient with myeloma relapses from initial treatment with high-dose melphalan and autologous stem cell transplantation (ASCT). For patients who experience a durable response to